Transfusion Medicine Reviews
Volume 24 , Pages S28-S50 , January 2010

The Use of Immunoglobulin Therapy for Patients With Primary Immune Deficiency: An Evidence-Based Practice Guideline

References 

  1. Primary Immune Deficiency Disease in America . The second national survey of patients. Available at http://www.primaryimmune.org/publications/surveys/second_national_survey_of_patients_(2002).pdfAccessed June 2008
  2. Leiva LE, Zelazco M, Oleastro M, et al. Primary immunodeficiency diseases in Latin America: The second report of the LAGID registry. J Clin Immunol. 2007;27:101–108
  3. Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007;27:517–524
  4. Bruton AC. Agammaglobulinemia. Pediatrics. 1952;9:722–728
  5. Nahirniak S, Hume H. Guidelines for the use of intravenous immune globulin for primary immune deficiency and solid organ transplantation. Transfus Med Rev. 2010;24(Suppl 1):S1–S6
  6. Canadian Task Force on Preventative Health Care. Available at http://www.ctfphc.org/Accessed June 2008
  7. Ho C, Membe S, Cimon K, et al. Subcutaneous versus intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic evaluation [technology report number 98]. Ottawa: Canadian Agency for Drugs and Technologies in Health. Available at http://www.cadth.ca/media/pdf/466_Subcutaneous-Versus-Intravenous-Immunoglobulin_tr_e.pdf2008;Accessed May 2008
  8. Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: A systematic review. Clin Exp Immunol. 2007;149:410–423
  9. National Institutes of Health . In: Intravenous immunoglobulin: prevention and treatment of disease: NIH consensus statement. vol. 8:Washington, DC: US Department of Health and Human Services, National Institutes of Health; 1990;p. 1–23
  10. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525–S553Review. Erratum in: J Allergy Clin Immunol 2006 Jun; 117(6): 1483. dosage error in text
  11. Primary Immunodeficiency Network UK . Administration of intravenous immunoglobulin. PIN Guideline No:2.01. Available at http://www.ukpin.org.uk/Accessed February 2008
  12. Buckley RH. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: Inadequacy of current dosage practices and approaches to the problem. J Clin Immunol. 1982;2(2 Suppl):15S–21S
  13. Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46:1547–1554
  14. Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27:308–316
  15. Notarangelo L, Casanova JL, Conley ME, et al. Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol. 2006;117:883–896
  16. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(Suppl):S1–S63
  17. Fleisher TA, Oliveira JB. Functional and molecular evaluation of lymphocytes. J Allergy Clin Immunol. 2004;114:227–234
  18. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93:190–197
  19. Aghamohammadi A, Pouladi N, Parvaneh N, et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatr. 2007;53:32–38
  20. Garbett ND, Currie DC, Cole PJ. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia. Clin Exp Immunol. 1989;76:1–7
  21. Ammann AJ, Ashman RF, Buckley RH, et al. Use of intravenous gamma-globulin in antibody immunodeficiency: Results of a multicenter controlled trial. Clin Immunol Immunopathol. 1982;22:60–67
  22. Nolte MT, Pirofsky B, Gerritz GA, et al. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol. 1979;36:237–243
  23. Olinder-Nielsen AM, Granert C, Forsberg P. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: A long-term follow-up. Scand J Infect Dis. 2007;9:44–50
  24. Cheng YK, Decker PA, O'Byrne MM, et al. Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome. Ann Allergy Asthma Immunol. 2006;97:306–311
  25. Pourpak Z, Aghamohammadi A, Sedighipoour L, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006;39:114–120
  26. Bayrakci B, Ersoy F, Sarial O, et al. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID).. Turk J Pediatr. 2005;47:239–246
  27. Santaella ML, Font I, Disdier O. Common variable immunodeficiency: experience in Puerto Rico. P R Health Sci J. 2005;24:7–10
  28. Aghamohammadi A, Moin M, Farhoudi A, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol. 2004;40:113–118
  29. De Garcia J, Vendrell M, Alvarez A, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol. 2004;4:745–753
  30. Busse PJ, Razvi S. Cunningham-Rundles. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.. J Allergy Clin Immunol. 2002;109:1001–1004
  31. Garcia MAM, de Rojas HF, Manzur N, et al. Respiratory disorders in common variable immunodeficiency. Respir Med. 2001;95:191–195
  32. Quartier P, Debré M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. J Pediatr. 1999;134:589–596
  33. Ersoy F, Tezcan I. Sanal O. Effects of intravenous immunoglobulin on clinical and immunological findings of patients with humoral immunodeficiency diseases. Turk J Pediatr. 1992;34:203–209
  34. Liese JG, Witergerst U, Tympner KD, et al. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. AJDC. 1992;146:335–339
  35. Williams P, White A. Wilson JA et al.. Penetration of administered IgG into the maxillary sinus and long-term clinical effects of intravenous immunoglobulin replacement therapy on sinusitis in primary hypogammaglobulinaemia.. Acta Otolaryngol. 1991;111:550–555
  36. Galli E, Barbieri C, Cantani A, et al. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: Clinical and immunologic follow-up. Ann Allergy. 1990;64(2 Pt. 1):147–150
  37. Silk HJ, Ambrosino D, Geha RS. Effect of intravenous gammaglobulin therapy in IgG2 deficient and IgG2 sufficient children with recurrent infections and poor response to immunization with Hemophilus influenzae type b capsular polysaccharide antigen. Ann Allergy. 1990;64:21–25
  38. Bernatowska E, Madalinski K, Janowicz W, et al. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol. 1987;43:153–162
  39. Cunningham-Rundles C, Siegal FP, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101:435–439
  40. Roifman CM, Lederman HM, Lavi S, et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985;79:171–174
  41. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1075–1077
  42. Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun Rev. 2006;5:465–470
  43. Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun. 2005;25:57–62
  44. Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore). 2004;83:254–263
  45. Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol. 2004;93:160–165
  46. Zebracki K, Palermo TM, Hostoffer R, et al. Health-related quality of life of children with primary immunodeficiency disease: A comparison study. Ann Allergy Asthma Immunol. 2004;93:557–561
  47. Daly PB, Evans JH, Kobayashi RH, et al. Home-based immunoglobulin infusion therapy: Quality of life and patient health perceptions. Ann Allergy. 1991;67:504–510
  48. Sorensen RU, Kallick MD, Berger M. Home treatment of antibody-deficiency syndromes with intravenous immune globulin. J Allergy Clin Immunol. 1987;80:810–815
  49. Kobayashi RH, Kobayashi AD, Lee N, et al. Home self-administration of intravenous immunoglobulin therapy in children. Pediatrics. 1990;85:705–709
  50. Ashida ER, Saxon A. Home intravenous immunoglobulin therapy by self-administration. J Clin Immunol. 1986;6:306–309
  51. Chapel H, Brennan V, Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol. 1988;73:160–162
  52. Brennan VM, Cochrane S, Fletcher C, et al. Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home. J Clin Immunol. 1995;15:116–119
  53. Chapel H, Brennan V. Self-infusion with immunoglobulin at home. J Clin Pathol. 1991;44:358–359
  54. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96:1474–1478
  55. Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.. Ann Intern Med. 2001;135:165–174
  56. Pruzanski W, Sussman G, Dorian W, et al. Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation. 1996;20:353–359
  57. Ochs HD, Fischer SH, Wedgewood RJ, et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med. 1984;76:78–82
  58. Favre O, Leimgruber A, Nicole A, et al. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy. 2005;60:385–390
  59. Montanaro A, Pirofsky B. Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med. 1984;76:67–72
  60. Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J Clin Invest. 1971;50:2559–2568
  61. Avanzini MA, Björkander J, Söderström R, et al. Qualitative and quantitative analyses of the antibody response elicited by Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in adults with IgG subclass deficiencies and frequent infections. Clin Exp Immunol. 1994;96:54–58
  62. Barra A, Bremard-Oury C, Bajart A, et al. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide and its tetanus toxoid conjugate in patients with recurrent infections or humoral immunodeficiency. Int J Clin Lab Res. 1992;21:231–234
  63. Plebani A, Fischer MB, Meini A, et al. T cell activity and cytokine production in X-linked agammaglobulinemia: implications for vaccination strategies. Int Arch Allergy Immunol. 1997;114:90–93
  64. Webster AD, Latif AA, Brenner MK, et al. Evaluation of test immunisation in the assessment of antibody deficiency syndromes. BMJ. 1984;288:1864–1866
  65. Ko J, Radigan L, Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol. 2005;116:37–41
  66. Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol. 2007;124:294–303
  67. Rezaei N, Aghamohammadi A, Siadat SD, et al. Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency. Clin Vaccine Immunol. 2008;15:607–611
  68. Piqueras B, Lavenu-Bombled C, Galicier L, et al. Common variable immunodeficiency classification based on impaired B cell memory differentiation correlated with clinical aspects. J Clin Immunol. 2003;23:385–400
  69. Warnatz K, Denz A, Dräger R, et al. Severe deficiency of switched memory B cells (CD27+ IgM−IgD− in subgroups of patients with common variable immunodeficiency: A new approach to classify a heterogeneous disease. Blood. 2002;99:1544–1551
  70. Deeks SL, Clark M, Scheifele DW, et al. Serious adverse events associated with bacille Calmette-Guérin vaccine in Canada. Pediatr Infect Dis J. 2005;24:538–541
  71. Casanova JL, Jouanguy E, Lamhamedi S, et al. Immunological conditions of children with BCG disseminated infection. Lancet. 1995;346:581;(letter)
  72. White WB, Desbonnet CR, Ballow M. Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobulinemia. Am J Med. 1987;83:431–436
  73. Ballow M, White W, Desbonnet C. Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity by therapy with intravenous immune globulin. J Allergy Clin Immunol. 1989;84(4 Pt. 2):595–601discussion 601-602
  74. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep. 1993;42:1–18
  75. Kroger AT, Atkinson WL, Marcuse EK, et al. General recommendations on immunization recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55:1–48
  76. Canadian Immunization Guide 7th edition. Available at http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-07-eng.phpAccessed May 2008
  77. Schiff RI, Williams LW, Nelson RP, et al. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol. 1997;17:21–28
  78. Matamoros N, De Gracia J, Hernández F, et al. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin. Int Immunopharmacol. 2005;5:619–626Erratum in: Int Immunopharmacol 513, 2006
  79. Lamari F, Karamanos NK, Papadopoulou-Alataki E, et al. Monitoring of two intravenous immunoglobulin reparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients. J Pharm Biomed Anal. 2000;22:1029–1036
  80. Björkander J, Nikoskelainen J, Leibl H, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006;90:286–293
  81. Ebeling F, Baer M, Hormila P, et al. Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients. Vox Sang. 1995;69:91–94
  82. Ballow M, Berger M, Bonilla FA, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang. 2003;84:202–210
  83. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003;3:1325–1333
  84. Mushiake K, Motoyoshi F, Kondo N, et al. Long-term follow up of patients with common variable immunodeficiency treated with intravenous immunoglobulin: reevaluation of intravenous immunoglobulin replacement therapy. IVIG therapy in CVID. Biotherapy. 1993-1994;7:101–107
  85. Zuhrie SR, Webster AD, Davies R, et al. A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin. Clin Exp Immunol. 1995;99:10–15
  86. Ochs HD, Pinciaro PJ Octagam Study Group. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol. 2004;24:309–314
  87. Berger M, Pinciaro PJ. Flebogamma 5% Investigators. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol. 2004;24:389–396
  88. Wolf HH, Davies SV, Borte M, et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang. 2003;84:45–53
  89. Ochs HD, Buckley RH, Pirofsky B, et al. Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet. 1980;2:1158–1159
  90. Berger M, Flebogamma 5% DIF Investigators . A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27:628–633
  91. Berger M, Cunningham-Rundles C, Bonilla FA, et al. Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol. 2007;27:503–509
  92. Yap PL, McClelland DB. An evaluation of the safety of three intravenous immunoglobulin preparations in patients with primary hypogammaglobulinaemia. J Infect. 1986;12:5–10
  93. Björkander J, Hammarström L, Smith CI, et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol. 1987;7:8–15
  94. Ferreira A, Garcia Rodriguez MC, Lopez-Trascasa M, et al. Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. Clin Immunol Immunopathol. 1988;47:199–207
  95. de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol. 2000;20:77–82
  96. Eijkhout HW, van den Broek PJ, van der Meer JW. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med. 2003;61:213–217
  97. Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol. 2007;122:156–162
  98. Lejtenyi D, Mazer B. Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J Allergy Clin Immunol. 2008;121:254–255
  99. Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child. 1996;74:527–530
  100. Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005;25(11 Pt. 2):78S–84S
  101. Brennan VM, Salomé-Bentley NJ, Chapel HM. Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133:247–251
  102. Aghamohammadi A, Farhoudi A, Nikzad M, et al. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann Allergy Asthma Immunol. 2004;92:60–64
  103. Struff WG, Klasser M, Eckert V, et al. Safety monitoring of a polyvalent immunoglobulin preparation: Documentation of 15,548 administrations. Int J Clin Pharmacol Ther. 2005;43:420–428
  104. Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: A 10-year prospective observational study. Pharmacoepidemiol Drug Saf. 2007;16:1038–1047
  105. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res. 2007;38:122–132
  106. Quinti I, Soresina A, Agostini C, et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol. 2008;28:263–267
  107. Ziegner UH, Kobayashi RH, Cunningham-Rundles C, et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol. 2002;102:19–24
  108. Scholl PR. Progressive encephalopathy in primary immunodeficiency disease. Clin Immunol. 2002;102:1
  109. Rudge P, Webster AD, Revesz T, et al. Encephalomyelitis in primary hypogammaglobulinaemia. Brain. 1996;119:1–15(Pt. 1)
  110. US. Food and Drug . Letter to manufacturers immune globulin intravenous (Human) (IGIV) required updates to product labeling. Available at http://www.fda.gov/cber/ltr/igiv101603.htmAccessed June 2008
  111. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA. 1996;276:1563–1567

 STATEMENT OF CONFLICT OF INTEREST: Dr Richard Warrington has received funding from Bayer Canada and from Baxter Canada. Dr Bruce Mazer has received research funding from the Bayer/Talecris Canadian Blood Services/Hema-Quebec Partnership Fund since 1995. He has received additional research funding from Bayer and Talecris. His department has received unrestricted educational grants from Bayer and CSL Behring. Dr Elie Haddad has received research funding from the Bayer/Talecris Canadian Blood Services/Hema-Quebec Partnership Fund since 2007. His department has received unrestricted educational grants from Bayer-Talecris and Baxter. He is an advisory board member for CSL Behring and Bristoll Myers Squibb. He has also received honoraria from Talecris, Novartis, and Baxter. Dr Bob Schellenberg is an advisory board member for CSL Behring and in previous years Bayer and Baxter. He is a recipient of a Grant-in-Aid from Bayer (now Talecris). Dr Nadine Shehata is an employee of Canadian Blood Services, as was Dr Heather Hume during the period of the development of these guidelines.

 Funding was provided from an unrestricted education grant from Bayer, Inc, to Canadian Blood Services. Bayer did not have any role in the selection of panel members, the literature search, the selection of articles, or in the development of the recommendations.

PII: S0887-7963(09)00091-1

doi: 10.1016/j.tmrv.2009.09.011

Transfusion Medicine Reviews
Volume 24 , Pages S28-S50 , January 2010

Article Tools